期刊
VACCINE
卷 27, 期 4, 页码 581-587出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.10.088
关键词
AS04; Adjuvant; Cervical cancer; HPV; Immunization
资金
- GlaxoSmithKline Biologicals, Rixensart, Belgium [105879/014]
The immunogenicity and safety of an HIIV-16/18 AS04-adjuvanted vaccine were assessed in women aged 26-55 years and compared with women aged 15-25 years in a Phase III, non-randomised, open-label, age-stratified study. Overall the vaccine was well tolerated and 100% seropositivity was achieved I month after the third dose in all age groups. There was a high correlation between HPV-16 and HPV-18 antibody levels (IgG) in cervicovaginal secretions and sera, regardless of age. The HPV-16/18 AS04-adjuvanted vaccine induces a robust and persistent immune response in women >26 years of age and generates antibodies that transudate through the cervix epithelium. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据